Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 2
2021 3
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Onco-nephrology: Physicians' Expectations About a New Subspecialty.
Delaye M, Try M, Rousseau A, Lafargue MC, Saillant A, Bainaud M, Andreani M, Rozenblat D, Campedel L, Corbaux P, Isnard-Bagnis C. Delaye M, et al. Among authors: corbaux p. J Cancer Educ. 2023 Jun;38(3):878-884. doi: 10.1007/s13187-022-02201-8. Epub 2022 Jul 15. J Cancer Educ. 2023. PMID: 35840858
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A. Corbaux P, et al. Eur J Cancer. 2023 Sep;191:112966. doi: 10.1016/j.ejca.2023.112966. Epub 2023 Jul 4. Eur J Cancer. 2023. PMID: 37542936 Free article.
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.
Lauby A, Colomban O, Corbaux P, Peron J, Van Wagensveld L, Gertych W, Bakrin N, Descargues P, Lopez J, Kepenekian V, Glehen O, Philip CA, Devouassoux-Shisheboran M, Tod M, Freyer G, You B. Lauby A, et al. Among authors: corbaux p. Cancers (Basel). 2021 Dec 25;14(1):98. doi: 10.3390/cancers14010098. Cancers (Basel). 2021. PMID: 35008262 Free PMC article. Review.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Corbaux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, Lévy C, Viansone AA, Mailliez A, Debled M, Goncalves A, Le Du F, Lerebours F, Ferrero JM, Eymard JC, Mouret-Reynier MA, Petit T, Frenel JS, Dalenc F, Courtinard C, Chaix M, Bachelot T. Corbaux P, et al. Breast Cancer Res Treat. 2022 Jan;191(1):191-207. doi: 10.1007/s10549-021-06382-6. Epub 2021 Oct 23. Breast Cancer Res Treat. 2022. PMID: 34687411
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes.
Bruyère CL, Souquet PJ, Dalle S, Corbaux P, Boespflug A, Duruisseaux M, Kiakouama-Maleka L, Reverdy T, Maugeais M, Sahin G, Maillet D, Péron J. Bruyère CL, et al. Among authors: corbaux p. Cancers (Basel). 2021 May 14;13(10):2365. doi: 10.3390/cancers13102365. Cancers (Basel). 2021. PMID: 34068892 Free PMC article.
Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study.
Maugeais M, Péron J, Dalle S, Boespflug A, Duruissaux M, Corbaux P, Reverdy T, Sahin G, Rabier A, Lopez J, Freymond N, Maillet D. Maugeais M, et al. Among authors: corbaux p. Biomedicines. 2022 Dec 29;11(1):83. doi: 10.3390/biomedicines11010083. Biomedicines. 2022. PMID: 36672591 Free PMC article.
15 results